Full name
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B (anti-IL33) in Participants With Bronchiectasis
NCT Number
NCT07201051
Geography
Non-US
Locations
TBD
Primary Endpoints
Annualized rate of Exacerbations for GSK3862995B Dose Level 1 Following Repeat Doses Compared with Placebo. Up to Week 48
Order
7
Disease
Version
Phase
2
Status
Not yet recruiting